Latest Mitochondrial disease Stories
Mitochondrial diseases disrupt the power generating machinery within cells and increase a person's susceptibility to bacterial infection, particularly in the lungs or respiratory tract.
Highly Sensitive Genetic Test Provides Early Diagnosis of Mitochondrial Diseases LOS ANGELES, June 9 /PRNewswire/ -- MEDomics, LLC (www.medomics.com) announces an innovative test for early diagnosis of mitochondrial diseases, a group of disorders that can result in neurological dysfunction, muscle weakness, gastrointestinal symptoms, migraine headaches, blindness, deafness, and diabetes.
Sensory ataxic neuropathy (SAN) is a recently identified neurological disorder in Golden Retriever dogs with onset during puppyhood. Affected dogs move in an uncoordinated manner and have sensory deficits.
NEW YORK, March 31 /PRNewswire/ -- Greg and Mindy Scheier announced today that they will be hosting OlliePalooza, a benefit for The United Mitochondrial Disease Foundation, in honor of their four year-old son, Oliver, on April 25, 2009 at Strata in New York City.
Scientists at Stanford University School of Medicine have devised a much-needed way to monitor and find treatments for a mysterious and devastating group of metabolic diseases that arise from mutations in cells' fuel-burning mechanism.
SafeMinds Asks, "Is Mercury a Common Factor?" WASHINGTON, Dec.
To: SPORTS EDITORS Contact: Cliff Gorski of the United Mitochondrial Disease Foundation, +1-412-793-8077, email@example.com Tampa Bay Rays' Baldelli's Miraculous Comeback an Inspiration To Those Suffering from Mitochondrial Disease PITTSBURGH, Oct.
By Brian Bowling Isabelle Christenson, 10, of Seven Fields in Butler County died at home Wednesday after losing her battle with mitochondrial disease.
To: NATIONAL EDITORS Contact: Cliff Gorski of United Mitochondrial Disease Foundation, 1-888-317-UMDF ext. 101, firstname.lastname@example.org Mutation Causing Mitochondrial Disease More Common Than Previously Believed PITTSBURGH, Aug.
SAN JOSE, Calif., July 15 /PRNewswire/ -- Edison Pharmaceuticals, Inc., a privately held biotechnology company located in San Jose, CA, announced today that EPI-A0001 (A0001) has entered clinical development, triggering a milestone payment from Penwest Pharmaceuticals, Edison's development partner.